Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404924 · ClinicalTrials.gov registry record · Phase 3
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
A Phase 3 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,140
- Enrollment target
NCT00404924 is a Phase 3 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 1,140 participants.
The verdict
NCT00404924, a Phase 3 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,140 participants
- Enrollment target
Study Summary
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.
Interventions
- OTHER Best Supportive Care
- DRUG ZD6474 (vandetanib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,140 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404924
The ClinicalTrials.gov registry entry for NCT00404924 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Best Supportive Care is the first listed.
NCT00404924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404924 about?
NCT00404924 is a clinical study titled "ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures". This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Ty...
What is the current status of trial NCT00404924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,140 participants. The study started on 2006-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00404924?
The interventions under investigation include: Best Supportive Care (OTHER), ZD6474 (vandetanib) (DRUG).
Who is sponsoring clinical trial NCT00404924?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.